Use of il-2 receptor antibodies to prevent toxicity associated with amphotericin b antimycotic therapy
CA 2500723 A1 · Owner: The University Of Mississippi Medical Center · Inventors: Gordon, Robert D.; Chapman, Stanley Willetts; Cleary, John D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to a method for treating a patient having a fungal infection. The invention comprises administering to the patient a therapeutically effective amount of a polyene antifungal (e.g. amphotericin B) in association with a therapeutically effective amount of a interleukin-2 inhibitor (e.g. chimeric or humanized monoclonal antibody that binds to the p55 subunit of the human interleukin-2 receptor and inhibits binding of interleukin-2 to an interleukin-2 receptor).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 1, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 1, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 1, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.